Stay Up to Date
with SHINE

SHINE Technologies announced today that Harrie Buurlage has been named Chief Commercial Officer of Isotopes. Buurlage, who has been the General Manager of SHINE Europe since 2019, will now oversee all commercial aspects of SHINE's therapeutic and diagnostic medical isotope divisions.

SHINE Technologies, and Curadh MTR Inc. announced today an expanded long-term supply agreement for medical isotopes that promises to reshape the landscape of cancer therapies.

SHINE has demonstrated clearly visible Cherenkov radiation produced by fusion for what is believed to be the first time in history. This visible evidence provides further proof that fusion can produce neutrons on par with some nuclear fission reactors.

SHINE President and Chief Strategy Officer Todd Asmuth joins the podcast ClimateForce, which says, "Check this podcast out if you want to learn a lot about nuclear fusion and that fusion can be used for more than just creating energy."

There are 43 fusion companies worldwide, including 25 in the United States, according to the latest Fusion Industry Association report. SHINE is one of three based in southern Wisconsin. Why is the state such a hot bed for fusion technology?

Todd Asmuth, president and chief strategy officer of SHINE, will give an invited panel presentation on “Demand and Supply of Medical Isotopes” during the 11th International Conference on Isotopes from July 27 in Saskatoon, Saskatchewan, Canada.

Representatives from Wisconsin's three fusion companies, including SHINE's Ross Radel, agreed in a July 18 discussion that Wisconsin has a head start most states don't enjoy when it comes to fusion. Read more about it in the Wisconsin State Journal.

BioForward takes a closer look at how Wisconsin has emerged as a global leader in theranostics, including how state industry leaders like SHINE are playing a playing a role.

A variety of news outlets covered our recent story about opening up the largest lutetium-177 production facility in North America. Check out all the media coverage.

Phoenix, an industry leader in neutron imaging for nondestructive testing, today announced an agreement with Pacific Scientific Energetic Materials Company, one of the largest manufacturers of pyrotechnic and energetic products in the U.S.

SHINE is opening the largest facility in North America dedicated to the production of non-carrier-added lutetium-177, a medical isotope used in targeted cancer therapies. It is expected to have an initial production capacity of 100,000 doses of Lu-177 per year, with the ability to further expand production capacity to 200,000 doses per year in the future.

Nuclear Engineering International took a closer look at SHINE's four-phased approach to advancing fusion. "For me," founder and CEO Greg Piefer says, "the lesson learned was that maybe there are things that can be done with fusion that can add value to the world and they may allow you to learn how to do fusion more cost effectively going forward."

Dr. Frederick Robertson, who brings a wealth of experience in building companies in the medical device, life science and pharmaceutical industries, has been appointed to SHINE's board of directors.

Imagine a world where we would never run out of clean, affordable energy—where any industry could thrive with unlimited access to fuel or electricity, and energy could be generated anywhere it’s needed. This is the promise of nuclear fusion energy. We just need to get there, writes Rodika Tollefson of Dell Perspectives in an article that features SHINE.

Deep Tech AI explores advancements in neutron radiography, including the potential for artificial intelligence to play a bigger role moving forward. It discusses how SHINE "uses technology developed for its eventual application in commercial-grade fusion power -- namely, the ability to fire a beam of deuterium atoms at tritium in a gas -- to produce a suitable neutron source."